Johnson & Johnson will present over 35 abstracts at the 2026 International Myeloma Society (IMS) Annual Meeting.
The data includes Phase 3 results and long-term follow-up for DARZALEX, TECVAYLI, CARVYKTI, and TALVEY. These findings evaluate the treatments specifically in earlier clinical settings.
The presentations demonstrate advances in achieving deeper and more durable patient responses. This research supports the company’s strategic goal of developing potential cures for multiple myeloma.